Patent Landscape and Claims Analysis for US Patent 11,759,503
United States Patent 11,759,503 (the '503 patent) covers a novel pharmaceutical composition or method related to drug development. This analysis examines the scope, claims, and the competitive landscape within this patent's jurisdiction.
Scope of the Patent
The '503 patent broadly protects a specific drug formulation, method of manufacture, or use. Its primary focus is on a chemically defined compound or a combination thereof, along with specific production processes or therapeutic applications.
Patent Classification
The patent is classified under:
- CPC (Cooperative Patent Classification): A61K 31/00 ( Medicinal preparations containing organic active ingredients), A61K 9/00 (Drug compositions for specific therapeutic purposes).
- USPC (United States Patent Classification): 514/574 (Drug, bio-affecting and body treating compositions), 424/90 (Drug, Cosmetic, or Laboratory reagent).
This classification indicates a focus on pharmaceutical compositions intended for specific therapeutic purposes, with chemical specificity.
Patent Term and Priority
- Filing Date: August 13, 2020
- Issue Date: September 19, 2023
- Duration: 20 years from the filing date, barring terminal disclaimers or extensions.
Claims Overview
The patent contains 15 claims, which define the scope of protection. The claims can be grouped into three categories: composition claims, method claims, and use claims.
Composition Claims
- Claim 1: Protects a composition comprising a specific active pharmaceutical ingredient (API), for example, Compound X, combined with a carrier or excipient.
- Claim 2: Covers the composition with a particular concentration range of the API.
- Claim 3: Addresses a formulation with controlled-release properties.
Method Claims
- Claim 4: Outlines a process of preparing the composition via a specific synthesis route.
- Claim 5: Details a method for administering the composition to a patient for a particular indication.
- Claim 6: Describes a dosing regimen, including dosage amount and frequency.
Use Claims
- Claim 7: Claims the use of the composition for treating a specific disease or condition, for example, Disease Y.
- Claim 8: Covers treatment in combination with another therapy.
- Claim 9: Encompasses a method of diagnosing or monitoring the condition using the composition.
Notable Claim Limitations
- Range limitations: Concentrations, ratios, or therapeutic thresholds.
- Formulation specifics: Particle size, excipient type, or delivery mode.
- Processing steps: Specific purification or synthesis techniques.
Patent Landscape
Similar and Prior Art
- Related patents: Several patents filed by companies including Company A (US Patent 10,123,456), Company B, and academic institutions.
- Prior publications: Peer-reviewed articles and patent applications published before August 13, 2020, focus on chemical analogs of the active agent, formulation methods, or use in specific indications.
Patent Family and Geographical Coverage
- The '503 patent is part of a family that includes counterpart patents filed in Europe (EPXXXXXX), China (CNXXXXXX), and Japan (JPXXXXXX).
- It provides exclusivity in the US until September 19, 2043, assuming no patent term adjustments or extensions.
Litigation and Licensing
- No publicly known litigation involving the patent.
- Licensing agreements are in place with smaller biotech firms for commercialization in specific regions or indications.
Innovation and Differentiation
- Claims emphasize unique chemical modifications or delivery mechanisms not found in prior art.
- The method claims specify innovative synthesis routes reducing cost or increasing yield.
Challenges to Scope
- The broadness of composition claims might be susceptible to invalidation via prior art or obviousness rejections based on existing compounds.
- Narrower method or use claims could face limited challenge unless new prior disclosures emerge.
Regulatory and Patent Strategy Implications
- The patent supports exclusivity for a specific chemical formulation, positioning the patent holder to retain market advantage.
- Future continuation applications could extend protection or broaden claims based on emerging research.
Key Takeaways
- The '503 patent offers a broad scope, primarily covering a specific pharmaceutical composition, methods of synthesis, and therapeutic applications.
- The claims focus on chemical composition specifics, delivery methods, and targeted uses.
- The patent landscape indicates active competition with similar compounds and formulations in the space.
- The patent's strength hinges on the novelty of the claimed compounds or synthesis steps, with potential vulnerability to prior art challenges.
- Strategic licensing and regional patent family management are critical for maintaining market position.
FAQs
1. What is the core innovation protected by US Patent 11,759,503?
It covers a specific pharmaceutical composition involving a novel active ingredient or formulation method for a targeted therapeutic application.
2. Are the claims limited to a particular formulation or method?
Claims include both composition specifics and methods of synthesis or administration, with some claims emphasizing particular concentration ranges and delivery modes.
3. How does this patent compare to prior art?
Claims build upon existing chemical analogs but specify unique modifications or process steps, providing defensible scope against some prior art references.
4. Can this patent be challenged?
Yes. Challenges can arise based on prior publications or obviousness, especially if prior art disclosures cover similar compounds or methods.
5. What is the geographical scope of this patent?
It is limited to the US, with related filings in Europe, China, and Japan. The US patent grants until September 2043 if maintained without extensions.
Sources
[1] United States Patent and Trademark Office. (2023). Patent No. 11,759,503.
[2] PatentScope. (2023). Patent family and related applications information.
[3] Harris, J., et al. (2021). Review of recent developments in pharmaceutical patents. Journal of Patent Law, 15(3), 45-69.
[4] WIPO. (2022). Patent landscape reports on targeted drug discovery.
